×
English
हिंदी
ગુજરાતી
Home
My Feed
Remove Ads
Get Premium Content
Go Pro @₹99
Credit Cards
Instant Loans
Apply Now
Credit Score
Refer & Earn ₹500
Refer Now
Finance Tracker
Learning Curve
Fixed Deposits
Business Loan
Vouchers
Markets
Markets
FII & DII Activity
Corporate Action
Research Advice
Earnings
Technical Trends
Stock Deals
Intraday Large Deals
Bonds
Webinar
Pre Market
Stock Scanner
Sector Analysis
Unlisted Shares
Stock Updates
PRO Stock Lists
Monsoon Tracker
Seasonality Analysis
Crypto Dashboard
Web Stories
Tax Calculator
Forum
Gold Rate
Silver Rate
IFSC Code Finder
Storyboard18
IPO
Economic Indicators
Economic Calendar
Global Markets
US Markets
ETFs
Indian Indices
News
News
Tech/Startups
Auto
Research
Opinion
Politics
Personal Finance
EPF Guide
Real Estate
Portfolio
Watchlist
Personal Finance
Personal Finance
Loans
Fixed Deposit Comparison
Fixed Deposit Interest Calculator
Moneycontrol - SecureNow Health Insurance ratings
Mutual Funds
Mutual Funds
Performance Tracker
Top ranked funds
My Portfolio
Top performing Categories
Forum
New Fund Offers
MF Simplified
Commodities
Mutual Funds
Gold Rate
Silver Rate
Currencies
Cryptocurrency
Media
Live TV & Shows
Video
Podcast
Photos
Invest Now
Trade like Experts
Invest in Unlisted Shares
Specials
Pharma Industry Conclave
Unlocking opportunities in Metal and Mining
#MFSummit2025
Moneycontrol mutual fund summit 2025
Advanced Technical Charts
International
Get App
Be a
Pro
Home
PRO
Markets
News
Editor’s Picks
Tech
India
Learning Curve
Portfolio
Watchlist
Commodities
MF
Personal Finance
Forum
Videos
you are here:
Home
News
Biocon Biologics
Biocon Biologics
Biocon Biologics names Deepali Naair as Global Head, Brand & Corp Comm
Biocon Biologics' success in biosimilars points to the future pathway for Indian pharma
Biocon Biologics' Bengaluru unit classified as voluntary action indicated by USFDA
Biocon Biologics secures USFDA approval for biosimilar product to treat ophthalmology conditions
Biocon stock falls 4% after subsidiary sells branded formulations biz to Eris Lifesciences
Eris Lifesciences’ insatiable appetite for growth is driving up its debt
Biocon Biologics signs 10-year supply deal with Eris Lifesciences for Rs 1242 crore
Biocon Biologics settles patent issue; paves way for launch of biosimilar product in Canada
Biocon Biologics inks pact with Sandoz for sale of 2 biosimilar products in Australia
Biocon Biologics, Sandoz sign pact to distribute adalimumab biosimilar Humira in Japan
Biocon Biologics completes integration of Viatris' biosimilar business in 120 countries
Eris Lifesciences to buy Biocon arm’s derma, nephro units; Eris, Biocon shares in focus
Eris acquires nephrology, dermatology brands of Biocon for Rs 366 crore
Biocon may list biosimilars business by 2025 first half - CEO
Biocon gets 8 observations from USFDA after inspection of Malaysia insulins facility
Biocon gains as arm takes over commercialization of biosimilars business
Biocon Biologics takes over Viatris' biosimilar business in over 70 countries
Biocon Biologics biosimilar to treat certain inflammatory diseases now available in US
Diabetes and cardiovascular diseases account for over 33% of Jan Aushadhi medicine sales, reveals govt data
Biocon Biologics elevates Shreehas Tambe as MD & CEO
Biocon Biologics completes acquisition of Viatris' global biosimilars business
Biocon Biologics inks out-licensing agreement with Yoshindo Inc
Biocon, Yoshindo partner to commercialise 2 biosimilar assets in Japan
Bribery case: CBI court rejects bail plea of Jt Drugs Controller, Biocon Biologics official, three others
CBI court to pronounce order in CDSCO bribery case today
View More
Home
Markets
Loans
SPIN
2
WIN
News
Portfolio